Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Interleukin-1beta promotes repair of the CNS.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Sex hormones and multiple sclerosis: another informative failure.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Dimethylfumarate Impairs Neutrophil Functions.
Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Dimethyl fumarate for multiple sclerosis.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Pages